Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
Recently, the Phase II clinical trial of RG002C0106 injection, an innovative drug independently developed by Rigerna for the treatment of complement-mediated diseases, has successfully completed the enrollment and dosing of the first patient.RG002C0106 is an siRNA drug independently developed by Rigerna based on its self-established small nucleic acid drug technology R&D platforms, including RIHOST®, RICMO®, and LICOD®.Is one of the world's first siRNA drugs targeting complement factor C3 to enter clinical stages., which demonstrated good safety and tolerability in the Phase I clinical trial, will soon announce the corresponding research findings at the 18th International IgA Nephropathy Conference to be held in Prague, Czech Republic, and has been invited to present the positive results of the Phase I clinical study.With the continuous advancement of clinical research, RG002C0106 injection is expected to provide a brand-new treatment strategy for patients with IgA nephropathy, effectively addressing the limitations and inadequacies of current therapeutic options in this field.Since its establishment in 2022, Suzhou Rigerna Therapeutics has rapidly built three proprietary technology platforms for small nucleic acid drug R&D — RIHOST® (design and screening technology), RICMO® (chemical modification technology), and LICOD® (in vivo delivery technology). These platforms have overcome key technical bottlenecks in the industry, enabling a multi-dimensional technological layout that spans from liver-targeting to non-liver tissue delivery, and achieving several breakthrough advancements.
At the same time, the company has established globally freely implementable delivery technologies in a variety of extrahepatic tissues, including kidneys, skeletal muscles, fat, heart, central nervous system, lungs, eyes, etc. Particularly, its kidney tissue delivery technology is at a leading level globally. Based on the above liver and liver-relatedDelivery technology for extrahepatic tissues, the company has established a rich pipeline of liver-targeted and extrahepatic tissue-targeted drugs, and through variousModel to advance preclinical and clinical development.In the afternoon of September 8, 2025, China Resources Double-Crane andRigernaUnder the attention of all parties, the cooperation agreement was officially signed to jointly develop the innovative small nucleic acid drug RG008, focusing on the field of chronic metabolic diseases, and committed to providing patients with more breakthrough treatment options. In the future, both parties will fully utilize their respective technical and industrialization advantages, work closely together, and strive to advance the project into the clinical stage as soon as possible.Source of the article:Rigerna
Mastering CAR-T Therapy, Stem Cell Therapy, and Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
